Kyverna Therapeutics Inc. took advantage of the growing excitement for chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of autoimmune diseases by raising $319m in an initial public offering – the second-largest of the seven biopharmaceutical IPOs so far in the US this year. The proceeds will fund ongoing and planned clinical trials for its lead CAR-T candidate, CD19-targeting KYV-101, in the treatment of lupus nephritis, systemic sclerosis, multiple sclerosis and myasthenia gravis.
IPO Gives Kyverna Cash To Maintain Lead In Autoimmune CAR-T Development
With Metagenomi And Telomir, US Offerings Total Seven
Kyverna CEO Peter Maag spoke with Scrip about the company’s five-year overnight success after its well-received IPO. Metagenomi and Telomir also went public in the US in smaller offerings.
More from Financing
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
More from Business
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.